Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Klein

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Annals of the New York Academy of Sciences|November 15, 2006
Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approachesYoussef Anouar, Laurent Yon, Johann Guillemot, et al.
Presse Medicale (Paris, France : 1983)|January 11, 2012
[Recommendations of the French Society of Endocrinology for the management of thyroid nodules]Jean-Louis Wémeau, Jean-Louis Sadoul, Michéle d'Herbomez, et al.
International Journal of Cancer|November 16, 2005
Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytomaJohann Guillemot, Youssef Anouar, Maïté Montero-Hadjadje, et al.
The Journal of Clinical Endocrinology and Metabolism|September 20, 2007
Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancyErwan Thouënnon, Abdel G Elkahloun, Johann Guillemot, et al.
European Journal of Endocrinology|May 6, 2022
Multiple endocrine neoplasia type 1 caused by mosaic mutation: clinical follow-up and genetic counseling?Lucie Coppin, Sophie Giraud, Eric Pasmant, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.
Thyroid : Official Journal of the American Thyroid Association|August 15, 2018
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid CancerFrancoise Borson-Chazot, Emmanuelle Dantony, Frederic Illouz, et al.
The Journal of Clinical Endocrinology and Metabolism|July 26, 2013
Is thyroid cancer recurrence risk increased after transplantation?Hélène Tisset, Nassim Kamar, Isabelle Faugeron, et al.
Thyroid : Official Journal of the American Thyroid Association|October 19, 2023
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF NetworkArnaud Jannin, Fabiola Giudici, Christelle de la Fouchardière, et al.
Annals of Surgery|December 27, 2018
Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d'étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne)Sandrine Vinault, Anne-Sophie Mariet, Maëlle Le Bras, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Annals of the New York Academy of Sciences|November 15, 2006
Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approachesYoussef Anouar, Laurent Yon, Johann Guillemot, et al.
Presse Medicale (Paris, France : 1983)|January 11, 2012
[Recommendations of the French Society of Endocrinology for the management of thyroid nodules]Jean-Louis Wémeau, Jean-Louis Sadoul, Michéle d'Herbomez, et al.
International Journal of Cancer|November 16, 2005
Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytomaJohann Guillemot, Youssef Anouar, Maïté Montero-Hadjadje, et al.
The Journal of Clinical Endocrinology and Metabolism|September 20, 2007
Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancyErwan Thouënnon, Abdel G Elkahloun, Johann Guillemot, et al.
European Journal of Endocrinology|May 6, 2022
Multiple endocrine neoplasia type 1 caused by mosaic mutation: clinical follow-up and genetic counseling?Lucie Coppin, Sophie Giraud, Eric Pasmant, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.
Thyroid : Official Journal of the American Thyroid Association|August 15, 2018
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid CancerFrancoise Borson-Chazot, Emmanuelle Dantony, Frederic Illouz, et al.
The Journal of Clinical Endocrinology and Metabolism|July 26, 2013
Is thyroid cancer recurrence risk increased after transplantation?Hélène Tisset, Nassim Kamar, Isabelle Faugeron, et al.
Thyroid : Official Journal of the American Thyroid Association|October 19, 2023
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF NetworkArnaud Jannin, Fabiola Giudici, Christelle de la Fouchardière, et al.
Annals of Surgery|December 27, 2018
Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d'étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne)Sandrine Vinault, Anne-Sophie Mariet, Maëlle Le Bras, et al.
Pageof 7